Transcranial Direct Current Stimulation of the Motor Cortex in Essential Tremor
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03952117 |
|
Recruitment Status : Unknown
Verified August 2019 by Rechdi Ahdab, Lebanese American University.
Recruitment status was: Recruiting
First Posted : May 16, 2019
Last Update Posted : August 13, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The current research is aimed at using Transcranial Direct Current Stimulation (tDCS) as complementary therapeutic tool in the treatment of essential tremor. Patients will be randomized into two groups (tDCS-cathode vs. tDCS-sham) according to detailed protocol. Main outcome will be measured by the change in tremor amplitude using an accelerometer pre and post cathodal tDCS of the motor cortex.
A total of 40 patients ought to be enrolled as specified in methodology. Secondary outcomes will assess TRG essential tremor rating assessment scale (TETRAS) as well as clinical monitoring.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Essential Tremor Transcranial Direct Current Stimulation | Device: transcranial direct current stimulation | Not Applicable |
Essential tremor (ET) is a common progressive neurological disorder and is the most common movement disorder. Worldwide , up to 5% of the population suffer from this disorder with an increased incidence with advanced age.
The proposed mechanism that underlies ET, the central oscillating network, is mainly composed of the olivocerebellar system, thalamus and motor cortex. An interruption in this circuit limits the ability of the cortex to reorganize and restore ET. a case of 76 year old female with essential tremor that disappeared following a cortico-subcortical prerolandic stroke despite complete motor recovery highlights the role of the motor cortex in the production and possible therapeutic role of the transcranial direct current stimulation.
Study design A randomized, sham-controlled, double blind and crossover study.
Study procedure:
The first visit is an inclusion visit Prior to starting the first tDCS session, the patient will be asked to fill his/her first TRG essential tremor assessment (TETRAS) scale. The physician will then quantitatively analyze the tremor on the most affected side using an accelerometer. Cathodal tDCS will be administered on the area representing the primary motor cortex and the anode over the contralateral supraorbital area. tDCS stimulation (cathodal and sham) will be done daily for 5 consecutive days during weeks 1 and 5. Each stimulation session will last 30 minutes. tDCS will be performed while the patient is at rest, without any concurrent cognitive or motor task.The two tDCS sessions will be separated by a 23 day washout period.
Patient will be asked to fill out their TETRAS at days 1 and 5 of each tDCS session (cathodal and sham), and days 12 and 19 after each tDCS session (cathodal and sham).
Accelerometer assessment of the tremor will be performed at days 1 and 5 of each tDCS stimulation session (cathodal and sham).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 40 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Transcranial Direct Current Stimulation of the Motor Cortex in Essential Tremor : A Randomized Controlled Pilot Study |
| Actual Study Start Date : | July 19, 2019 |
| Estimated Primary Completion Date : | June 2021 |
| Estimated Study Completion Date : | October 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Active tDCs
Active tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator. The cathode will be positioned facing the primary motor cortex area and the anode over the contralateral supraorbital area.
|
Device: transcranial direct current stimulation
tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland). |
|
Sham Comparator: Sham tDCS
Sham stimulation will be delivered to the motor cortex using a sham tDCS device that delivers a direct current for 10 seconds at the beginning and end of tDCS to provide sensory experiences similar to active stimulation.
|
Device: transcranial direct current stimulation
tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland). |
- Tremor amplitude [ Time Frame: 5 days ]Change in tremor amplitude using an accelerometer pre and post cathodal tDCS of the motor cortex.
- Functional impact of tremor [ Time Frame: 19 days ]Assess change from baseline of the functional impact of tremor using the TETRAS scale
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients who fulfil the 2017 Movement society concusses statement criteria for essential tremor
Exclusion Criteria:
- Isolated focal tremor (voice, head)
- Orthostatic tremor with a frequency of more than 12 Hz
- Task and position specific tremor
- Sudden onset and stepwise deterioration of tremor
- History of substance abuse or dependence in the past
- Co-morbid medical conditions capable of producing or enhancing tremors
- Use of a medication with potential effect on tremor
- History of neurological disorders, brain tumors, brain surgery or abnormal neurological examination
- Epileptic disorders
- Cardiac pacemakers
- Metallic hardware in the head or scalp (surgical clips)
- Eczema or skin abrasion at the intended site of stimulation
- Currently pregnant or plan for pregnancy in the next 6 months
- Patients with prior experience with tDCS
- Major psychosocial problems or medical problems rendering informed consent impossible
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03952117
| Contact: Naji Riachi, MD | 009611200800 ext 6312 | Naji.riachi@lau.edu.lb |
| Lebanon | |
| LAUMCRH | Recruiting |
| Beirut, Lebanon | |
| Contact: Naji Riachi, MD 009611200800 ext 6312 Naji.riachi@lau.edu | |
| Principal Investigator: | Rechdi Ahdab | Lebanese American University Medical Center |
Documents provided by Rechdi Ahdab, Lebanese American University:
| Responsible Party: | Rechdi Ahdab, M.D , PhD, Lebanese American University |
| ClinicalTrials.gov Identifier: | NCT03952117 |
| Other Study ID Numbers: |
LAUMCRH.RA3.11/Apr/2019 |
| First Posted: | May 16, 2019 Key Record Dates |
| Last Update Posted: | August 13, 2019 |
| Last Verified: | August 2019 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Product Manufactured in and Exported from the U.S.: | Yes |
|
primary motor cortex |
|
Tremor Essential Tremor Dyskinesias Neurologic Manifestations |
Nervous System Diseases Movement Disorders Central Nervous System Diseases |

